70-year-old-woman with extremely dense breasts

70-year-old-woman with extremely dense breasts. A. Axial subtracted contrast-enhanced fat-suppressed T1-weighted image from baseline AB-MR examination is negative (BI-RADS category 1). B. Axial subtracted contrast-enhanced fat-suppressed T1-weighted image from subsequent-round AB-MR examination performed 2 years later shows new 5-mm enhancing mass in upper outer right breast (arrow), which was not seen on mammogram performed 5 months prior. Examination was assessed as BI-RADS category 5. Ultrasound-guided core biopsy yielded invasive ductal carcinoma (ER+/PR+/HER2-).


June 6, 2024 — Subsequent rounds of abbreviated breast MRI (AB-MR) screening in patients with dense breasts had lower abnormal interpretation rate (AIR) compared to baseline examinations, while maintaining high cancer detection rate (CDR), according to the American Journal of Roentgenology (AJR).

Pointing out that all cancers detected by subsequent-round examinations were early-stage node-negative cancers, “further investigations are warranted to optimize the screening interval,” noted first author Christine E. Edmonds, MD, from the Hospital of the University of Pennsylvania. “The findings support sequential AB-MR for supplemental screening in individuals with dense breasts.”

AJR Editor in Chief Andrew Rosenkrantz, MD, speaks with Dr. Edmonds about her study comparing outcomes between baseline and subsequent rounds of screening abbreviated breast MRI in individuals with dense breasts.

Edmonds et al.’s AJR accepted manuscript included patients with dense breasts, at otherwise average breast-cancer risk, who underwent AB-MR for supplemental screening between December 20, 2016 and May 10, 2023. After extracting clinical interpretations and results of recommended biopsies for AB-MR examinations from the EMR, the researchers compared baseline and subsequent-round AB-MR examinations.

Ultimately, in women with dense breasts, subsequent-round AB-MR for supplemental screening achieved lower AIR versus baseline rounds (7.8% vs. 17.4%, p <.001), while maintaining high CDR (12.1 vs. 18.9 per 1000, p =.37). All cancers diagnosed by subsequent round AB-MR were stage 0 or 1; had size of 0.3-1.2 cm; and exhibited node-negative status.

For more information: www.arrs.org


Related Content

News | Breast Imaging

Dec. 01, 2025 — DeepHealth, a wholly owned subsidiary of RadNet, Inc., has launched the DeepHealth Breast Suite,2 an end ...

Time December 04, 2025
arrow
News | Women's Health

Dec. 1, 2025 — ScreenPoint Medical has completed a commercial agreement making its Transpara breast-imaging AI portfolio ...

Time December 03, 2025
arrow
News | Mammography

Nov. 30, 2025 — At RSNA 2025, Siemens Healthineers will introduce new capabilities for its Mammomat B.brilliant ...

Time December 02, 2025
arrow
News | RSNA 2025

Dec. 2, 2025 — Lunit, a provider of AI for cancer diagnostics and precision oncology, will present 14 studies at RSNA ...

Time December 02, 2025
arrow
News | Women's Health

Dec. 1, 2025 — A study of data from seven outpatient facilities in the New York region found that 20-24% of all the ...

Time December 02, 2025
arrow
News | Mammography

Nov. 26, 2025 — GE HealthCare has announced it received FDA Premarket Authorization for Pristina Recon DL, an advanced ...

Time November 29, 2025
arrow
News | Artificial Intelligence

Nov. 25, 2025 – Medical imaging AI company Avicenna.AI has announced a strategic partnership with Ferrum, an AI ...

Time November 25, 2025
arrow
News | Ultrasound Imaging

Nov. 12, 2025 — GE HealthCare and DeepHealth, Inc., a wholly owned subsidiary of RadNet, Inc., have announced their ...

Time November 20, 2025
arrow
News | Breast Imaging

Nov. 17, 2025 — RadNet, Inc. and its wholly owned subsidiary, DeepHealth have announced results from the largest real ...

Time November 17, 2025
arrow
News | Radiology Business

Nov. 12, 2025 — Siemens has announced plans to deconsolidate its remaining stake in Siemens Healthineers (currently ...

Time November 13, 2025
arrow
Subscribe Now